Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Key facts

Sponsor

Merck Sharp & Dohme LLC

Principal Investigator

Medical Director

Merck Sharp & Dohme LLC

Intervention

Pembrolizumab(biological)

Enrollment

864 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2026

Study locations (30)

• City of Hope ( Site 0102), Duarte, California, United States
• MedStar Washington Hospital Center ( Site 0186), Washington D.C., District of Columbia, United States
• James Graham Brown Cancer Center ( Site 0117), Louisville, Kentucky, United States
• Norton Cancer Institute ( Site 0116), Louisville, Kentucky, United States
• Johns Hopkins Bayview Medical Center ( Site 0152), Baltimore, Maryland, United States
• UMASS Memorial Medical Center ( Site 0120), Worcester, Massachusetts, United States
• Capital Health Medical Center - Hopewell ( Site 0189), Pennington, New Jersey, United States
• Hematology-Oncology Associates of CNY ( Site 0173), East Syracuse, New York, United States
• Memorial Sloan Kettering Cancer Center ( Site 0132), New York, New York, United States
• Weill Cornell Medical College ( Site 0133), New York, New York, United States
• St. Luke's University Health Network ( Site 0185), Bethlehem, Pennsylvania, United States
• AHN Allegheny General Hospital ( Site 0164), Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina-Hollings Cancer Center ( Site 0177), Charleston, South Carolina, United States
• VCU Health Adult Outpatient Pavillion ( Site 0160), Richmond, Virginia, United States
• Seattle Cancer Care Alliance ( Site 0145), Seattle, Washington, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of the esophagus

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07457528
  Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07331155
  A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
  Nanjing Leads Biolabs Co.,Ltd
• RECRUITINGPHASE1NCT07503808
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  IDEAYA Biosciences
• RECRUITINGPHASE2NCT07403136
  Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT07385001
  A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
  Tang-Du Hospital
• RECRUITINGPHASE2NCT07263919
  Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
  Akeso
• RECRUITINGPHASE2NCT07481058
  KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
  Beijing Konruns Pharmaceutical Co., Ltd.
• RECRUITINGPHASE1NCT07217171
  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  EvolveImmune United, Inc

See all trials for Squamous cell carcinoma of the esophagus →